CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis have demonstrated substantial clinical activity in metastatic NSCLC and received regulatory approval for use as first or subsequent lines of therapy [1–5].